New clinical research shows that systemic administration of a Vyriad-engineered oncolytic measles virus can significantly enhance T cell responses against multiple tumor-associated antigens (TAAs) in heavily pre-treated patients with advanced multiple myeloma. The study was recently published online in Leukemia, a peer-reviewed medical journal from Nature Publishing Group.
Expression of MAGE-C1, MAGE-A3 and other TAAs may promote myeloma cell survival and proliferation. Vyriad’s oncolytic measles virus (MV-NIS) infects and kills myeloma cells, resulting in phagocytosis and the critical presentation of TAAs that enlists antitumor cytotoxic T cell responses. This may lead to killing of both infected and uninfected cancer cells.
The study was conducted by researchers at Vyriad, Mayo Clinic and Baylor College of Medicine.
Vyriad’s MV-NIS is currently being evaluated in early stage clinical trials in urothelial carcinoma, recurrent medulloblastoma or atypical teratoid rhabdoid tumor.